VU534
VU534 is a NAPE-PLD activator, with an EC50 of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH (IC50 of 1.2 μM) . VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study [1] .
Product Specifications
CAS Number
923509-20-0
UNSPSC
12352005
Target
Beta-lactamase; Epoxide Hydrolase; FAAH
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/vu534.html
Purity
98.53
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
CC1=CC(C)=C2SC(NC(C3CCN(S(=O)(C4=CC=C(C=C4)F)=O)CC3)=O)=NC2=C1
Molecular Formula
C21H22FN3O3S2
Molecular Weight
447.55
References & Citations
[1]Jonah E Zarrow, et al. Small Molecule Activation of NAPE-PLD Enhances Efferocytosis by Macrophages. ACS Chem. Biol. 2023, 18, 8, 1891–1904.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Anti-Human NGF/Beta-NGF Antibody (SAA0435), APC
Anti-Human NGF/Beta-NGF Antibody (SAA0435), APC
Anti-Human NGF/Beta-NGF Antibody (SAA0435), APC